1. Home
  2. FGEN vs UBX Comparison

FGEN vs UBX Comparison

Compare FGEN & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • UBX
  • Stock Information
  • Founded
  • FGEN 1993
  • UBX 2009
  • Country
  • FGEN United States
  • UBX United States
  • Employees
  • FGEN N/A
  • UBX N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • UBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGEN Health Care
  • UBX Health Care
  • Exchange
  • FGEN Nasdaq
  • UBX Nasdaq
  • Market Cap
  • FGEN 34.5M
  • UBX 38.6M
  • IPO Year
  • FGEN 2014
  • UBX 2018
  • Fundamental
  • Price
  • FGEN $0.52
  • UBX $1.98
  • Analyst Decision
  • FGEN
  • UBX Strong Buy
  • Analyst Count
  • FGEN 0
  • UBX 2
  • Target Price
  • FGEN N/A
  • UBX $7.00
  • AVG Volume (30 Days)
  • FGEN 709.3K
  • UBX 335.8K
  • Earning Date
  • FGEN 02-24-2025
  • UBX 11-04-2024
  • Dividend Yield
  • FGEN N/A
  • UBX N/A
  • EPS Growth
  • FGEN N/A
  • UBX N/A
  • EPS
  • FGEN N/A
  • UBX N/A
  • Revenue
  • FGEN $180,015,000.00
  • UBX N/A
  • Revenue This Year
  • FGEN $21.91
  • UBX N/A
  • Revenue Next Year
  • FGEN N/A
  • UBX $33.62
  • P/E Ratio
  • FGEN N/A
  • UBX N/A
  • Revenue Growth
  • FGEN 16.15
  • UBX N/A
  • 52 Week Low
  • FGEN $0.18
  • UBX $0.94
  • 52 Week High
  • FGEN $2.80
  • UBX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 53.72
  • UBX 51.50
  • Support Level
  • FGEN $0.46
  • UBX $1.81
  • Resistance Level
  • FGEN $0.51
  • UBX $2.39
  • Average True Range (ATR)
  • FGEN 0.04
  • UBX 0.24
  • MACD
  • FGEN -0.00
  • UBX -0.06
  • Stochastic Oscillator
  • FGEN 78.67
  • UBX 26.56

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Share on Social Networks: